About MeiraGTxMeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders.
CEO: Alexandria Forbes
CSO: Robin Ali
CDO: Stuart Naylor
COO: Richard Giroux
Please click here for clinical trial information.
19 articles with MeiraGTx
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
10/9/2018MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
6/8/2018Three clinical-stage biotechnology companies announced initial public offerings (IPOs) today. Here’s a summary.
5/15/2018MeiraGTx has filed with the U.S. Securities and Exchange Commission (SEC) its intentions to launch an initial public offering (IPO).
MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by U.S. FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiency
MeiraGTx Limited, a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene.
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.
MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy product candidate A002 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGB3 gene.
The collaboration will enable MeiraGTx and Oxford Genetics to develop novel AAV vectors, as well as packaging and producer cell lines to support the manufacturing needs of MeiraGTx's pipeline of gene therapy product candidates.
MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Leber's Congenital Amaurosis and Treats First Pediatric Patient in Phase I/II Clinical Trial
The primary endpoint of the study is to determine the safety of the treatment. Secondary endpoints include improvement in visual function including a mobility maze, retinal function, retinal structure and quality of life measures.
The collaboration will enable Oxford Genetics and MeiraGTx to develop novel AAV vectors, as well as packaging and producer cell lines.
MeiraGTx Provides Clinical Trial Updates For X-Linked Retinitis Pigmentosa And Achromatopsia Gene Therapy Programs
MeiraGTx Provides Clinical Trial Updates For Achromatopsia And Leber's Congenital Amaurosis Ocular Gene Therapy Programs
MeiraGTx Granted Orphan Drug Designation For Its A004 Gene Therapy Treatment For Retinitis Pigmentosa
MeiraGTx Expands Neurodegenerative Gene Therapy Pipeline In Alzheimer's And Parkinson's Disease In Collaboration With Weill Cornell Medicine